In recent years, immunotherapy mainly based on immune checkpoint inhibitors (ICIs), such as anti-PD1/PD-L1 and anti-CTLA-4 antibodies, has significantly altered the landscape of cancer treatment, including lung cancer (Borghaei et al., 2015; Billan et al., 2020). Here, CTLA4 is linked to lung carcinoma.